Efficacy of lenvatinib/lenvatinib (Lenvima) in the treatment of liver cancer

In the systemic treatment of advanced hepatocellular carcinoma, lenvatinib has become one of the representative targeted therapies in international guidelines. Its efficacy evaluation is mainly based on its ability to synergistically inhibit tumor angiogenesis and multiple growth signaling pathways, making it occupy an important position in the first-line treatment of unresectable liver cancer. Research generally believes that lenvatinib provides liver cancer patients with an effective treatment option in addition to traditional targeted drugs.

In an international multi-center study, lenvatinib was confirmed to be non-inferior to the classic targeted drug sorafenib in terms of overall survival benefit. This result laid a solid foundation for its application in the treatment of liver cancer. More importantly, from the perspective of disease control rate and tumor shrinkage trend, lenvatinib shows more positive anti-tumor activity in some patients, which is particularly critical for patients with hepatocellular carcinoma who need to quickly control the progression of lesions.

In clinical practice, when doctors evaluate the efficacy of lenvatinib, they do not rely solely on survival time indicators, but pay more attention to its comprehensive impact on tumor burden, imaging response, and patient quality of life. Multiple real-world studies have shown that lenvatinib has a relatively controllable performance in maintaining stable liver function, allowing some patients to smoothly transition to subsequent treatment stages, which is of great significance in the long-term management of liver cancer.

In addition, the efficacy advantage of lenvatinib in the treatment of liver cancer is also reflected in its ability to create conditions for subsequent immunotherapy or combination therapy. Studies believe that lenvatinib is not only an effective targeted drug alone, but also an important component of modern comprehensive treatment strategies for liver cancer. Overall, the efficacy of lenvatinib in the treatment of hepatocellular carcinoma has been widely recognized by the international medical community, and its rational application can help prolong patient survival and improve the quality of disease control.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima